We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BAC and Octapharma Extend Recombinant Factor IX Collaboration for Clinical and Commercial Scale Production, and Initiate a Further Blood Disorder Programme
News

BAC and Octapharma Extend Recombinant Factor IX Collaboration for Clinical and Commercial Scale Production, and Initiate a Further Blood Disorder Programme

BAC and Octapharma Extend Recombinant Factor IX Collaboration for Clinical and Commercial Scale Production, and Initiate a Further Blood Disorder Programme
News

BAC and Octapharma Extend Recombinant Factor IX Collaboration for Clinical and Commercial Scale Production, and Initiate a Further Blood Disorder Programme

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BAC and Octapharma Extend Recombinant Factor IX Collaboration for Clinical and Commercial Scale Production, and Initiate a Further Blood Disorder Programme"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Octapharma produces FIX for the treatment of bleeding in Haemophilia B. The licence agreement follows on from successful completion of feasibility studies. Concurrently, the companies have embarked on a new discovery programme under which BAC will develop a CaptureSelect affinity ligand for the purification of recombinant human granulocyte-colony stimulating factor (G-CSF), which has applications in oncology and haematology.

Under the terms of the FIX agreement Octapharma will have licence to use BAC’s anti-FIX ligand for the purification of FIX from mammalian cell culture. Under the terms of the G-CSF agreement BAC will perform ligand discovery and development to provide an anti-G-CSF ligand, which will then undergo feasibility studies at Octapharma.

Factor IX is an essential product for the prophylaxis and treatment of bleeding in Haemophilia B, an X-linked recessive blood disorder that affects around 1 in 30,000 men. Octapharma currently markets a plasma-derived FIX product and is now progressing its recombinant FIX project. G-CSF is a hormone that stimulates bone marrow to produce white blood cells and stem cells, and has therapeutic uses in oncology and haematology.

Advertisement